Drug Trial News

RSS

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, today announced top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS).

23 Mar 2015

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).

23 Mar 2015

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Patients with acute coronary syndrome undergoing angioplasty who received the anticoagulant drug bivalirudin did not show significant improvements in either of two co-primary endpoints--a composite of rate of death, heart attack or stroke at 30 days, or a composite of those events plus major bleeding--as compared to patients receiving standard anticoagulation therapy, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.

23 Mar 2015

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.

21 Mar 2015

Targeted drug doubles progression free survival in Hodgkin lymphoma

A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months).

19 Mar 2015

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA) will be highlighted at the 2015 American Association for Cancer Research Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA.

19 Mar 2015

PaMZ drug regimen shows potential to improve treatment for MDR-TB

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.

19 Mar 2015

First clinical trial of new malaria vaccine held in Equatorial Guinea

Equatorial Guinea has held the first clinical trial of a new malaria vaccine known as PfSPZ. Three volunteers participated this month in the trial of the vaccine, which was developed by the American biotechnology company Sanaria. The trial took place at the La Paz Medical Center, the country's premier medical facility, located in Sipopo, just outside the capital.

18 Mar 2015

New study gives glimmer of hope for personalizing treatment for adrenal cancer

A new international study gives a glimmer of hope for personalizing treatment for one of the most rare and aggressive forms of cancer.

18 Mar 2015

Extended dual antiplatelet therapy after DES implantation increases mortality

Data from a meta-analysis published today in The Lancet found that extended duration dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation was associated with significantly higher rates of mortality compared to shorter DAPT.

18 Mar 2015

New drug fails to prevent irreversible injury to the heart after angioplasty

Patients who received the new drug Bendavia before undergoing angioplasty or receiving a stent to clear blocked arteries after a heart attack showed no significant reduction in scarring as compared to patients given a placebo, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session.

18 Mar 2015

New vaccine for post exposure treatment of rabies infection enters human clinical trial

Yisheng Biopharma Co., Ltd., a biopharmaceutical company focusing on the research, development, manufacturing, sales and marketing of vaccine products, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide.

16 Mar 2015

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04.

16 Mar 2015

Novimmune tests NI-0501 as first-line treatment for hemophagocytic lymphohistiocytosis

Novimmune SA announces that patients diagnosed with hemophagocytic lymphohistiocytosis (HLH), and who are participating in the company's ongoing clinical trial of its NI-0501 monoclonal antibody, will now be able to be treated with the drug without having to first fail conventional treatments.

16 Mar 2015

New antibody treatment blocks immune signaling protein crucial to psoriasis

Many patients suffering from psoriasis showed significant recovery after just a single dose of an experimental treatment with a human antibody that blocks an immune signaling protein crucial to the disease, researchers report.

16 Mar 2015

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.

16 Mar 2015

Combined use of enalapril and folic acid can significantly reduce risk of first stroke

In a study that included more than 20,000 adults in China with high blood pressure but without a history of stroke or heart attack, the combined use of the hypertension medication enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the American College of Cardiology Annual Scientific Session.

16 Mar 2015

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization Application (MAA) for SB2, its Remicade (Infliximab) biosimilar candidate, has been submitted to the European Medicines Agency (EMA).

13 Mar 2015

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.

12 Mar 2015

Promising new natural treatment for Alzheimer's disease nears clinical trial

A promising new natural treatment for Alzheimer's disease is moving toward clinical trials. This will be a major step forward as there is nothing on the market that slows the progression of Alzheimer's.

12 Mar 2015

Drug Trial News

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Anticoagulant drug bivalirudin shows mixed results in MATRIX trial

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Targeted drug doubles progression free survival in Hodgkin lymphoma

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

PaMZ drug regimen shows potential to improve treatment for MDR-TB

First clinical trial of new malaria vaccine held in Equatorial Guinea

New study gives glimmer of hope for personalizing treatment for adrenal cancer

Extended dual antiplatelet therapy after DES implantation increases mortality

New drug fails to prevent irreversible injury to the heart after angioplasty

New vaccine for post exposure treatment of rabies infection enters human clinical trial

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

Novimmune tests NI-0501 as first-line treatment for hemophagocytic lymphohistiocytosis

New antibody treatment blocks immune signaling protein crucial to psoriasis

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Combined use of enalapril and folic acid can significantly reduce risk of first stroke

Samsung Bioepis submits second biosimilar candidate MAA to EMA

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Promising new natural treatment for Alzheimer's disease nears clinical trial

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News